Revance Therapeutics reported $-64342000 in Net Income for its first fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Net Income Change
Abbvie ABBV:US $ 924M 3566M
Aerie Pharmaceuticals AERI:US $ -19.37M 16.52M
ALKERMES ALKS:US $ -30.14M 5.77M
Bristol Myers Squibb BMY:US $ 1421M 143M
Cara Therapeutics CARA:US $ -4206000 23.54M
Eli Lilly And LLY:US $ 952.5M 950.4M
Endo International Ordinary Shares ENDP:US $ -71.97M 490.09M
Horizon Pharma HZNP:US $ 60.97M 143.29M
JAZZ PHA JAZZ:US $ 34.66M 33.02M
Johnson & Johnson JNJ:US $ 4814M 335M
Merk MRK:US $ 3944M 366M
Neurocrine Biosciences NBIX:US $ -16.9M 30.8M
Pacira Pharmaceuticals PCRX:US $ 19.88M 13.05M
Procter & Gamble PG:US $ 3052M 303M
Revance Therapeutics RVNC:US $ -64.34M 1.24M
Supernus Pharmaceuticals SUPN:US $ 7.86M 17.75M
Teva Pharmaceutical Industries TEVA:US $ -233M 722M